Literature DB >> 6282196

Metabolism of acyclovir in virus-infected and uninfected cells.

P A Furman, P de Miranda, M H St Clair, G B Elion.   

Abstract

The metabolism of acyclovir to its mono-, di-, and triphosphate derivatives was examined in uninfected and virus-infected cells. The level of phosphorylation of acyclovir was dependent upon virus type, cell line, exogenous drug concentration, and exposure time. Acyclovir phosphorylation was inhibited by exogenously added nucleosides. The order of inhibition was deoxythymidine greater than deoxycytidine greater than guanosine greater than or equal to deoxyguanosine. Acyclovir triphosphate persisted in infected cells after removal of the drug from the medium. The initial half-life of the triphosphate was 1.2 h in the absence of the drug in the medium, but triphosphate levels reached a plateau after 6 h. The presence of low concentrations of the drug in the medium resulted in a longer persistence of the intracellular triphosphate and a higher plateau level.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6282196      PMCID: PMC181735          DOI: 10.1128/AAC.20.4.518

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  14 in total

1.  Thymidine kinase from herpes simplex virus phosphorylates the new antiviral compound, 9-(2-hydroxyethoxymethyl)guanine.

Authors:  J A Fyfe; P M Keller; P A Furman; R L Miller; G B Elion
Journal:  J Biol Chem       Date:  1978-12-25       Impact factor: 5.157

2.  Selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxymethyl) guanine.

Authors:  G B Elion; P A Furman; J A Fyfe; P de Miranda; L Beauchamp; H J Schaeffer
Journal:  Proc Natl Acad Sci U S A       Date:  1977-12       Impact factor: 11.205

3.  Inhibition by acyclovir of cell growth and DNA synthesis of cells biochemically transformed with herpesvirus genetic information.

Authors:  P A Furman; P V McGuirt; P M Keller; J A Fyfe; G B Elion
Journal:  Virology       Date:  1980-04-30       Impact factor: 3.616

4.  9-(2-hydroxyethoxymethyl) guanine activity against viruses of the herpes group.

Authors:  H J Schaeffer; L Beauchamp; P de Miranda; G B Elion; D J Bauer; P Collins
Journal:  Nature       Date:  1978-04-13       Impact factor: 49.962

5.  Stimulation of cellular thymidine kinases by human cytomegalovirus.

Authors:  J E Estes; E S Huang
Journal:  J Virol       Date:  1977-10       Impact factor: 5.103

6.  Inhibition of herpes simplex virus-induced DNA polymerase activity and viral DNA replication by 9-(2-hydroxyethoxymethyl)guanine and its triphosphate.

Authors:  P A Furman; M H St Clair; J A Fyfe; J L Rideout; P M Keller; G B Elion
Journal:  J Virol       Date:  1979-10       Impact factor: 5.103

7.  Deoxythymidine kinase induced in HeLa TK- cells by herpes simplex virus type I and type II. II. Purification and characterization.

Authors:  Y C Cheng; M Ostrander
Journal:  J Biol Chem       Date:  1976-05-10       Impact factor: 5.157

8.  Acyclovir kinetics after intravenous infusion.

Authors:  P de Miranda; R J Whitley; M R Blum; R E Keeney; N Barton; D M Cocchetto; S Good; G P Hemstreet; L E Kirk; D A Page; G B Elion
Journal:  Clin Pharmacol Ther       Date:  1979-12       Impact factor: 6.875

9.  The activity in vitro against herpes virus of 9-(2-hydroxyethoxymethyl)guanine (acycloguanosine), a new antiviral agent.

Authors:  P Collins; D J Bauer
Journal:  J Antimicrob Chemother       Date:  1979-07       Impact factor: 5.790

10.  Thymidine transport in herpesvirus hominis type 1 and 2 infected BHK 21 cells.

Authors:  K Bittlingmaier; D Schneider; D Falke
Journal:  J Gen Virol       Date:  1977-04       Impact factor: 3.891

View more
  33 in total

1.  Phosphorylation of beta-D-ribosylbenzimidazoles is not required for activity against human cytomegalovirus.

Authors:  Paula M Krosky; Katherine Z Borysko; M Reza Nassiri; Rodrigo V Devivar; Roger G Ptak; Michelle G Davis; Karen K Biron; Leroy B Townsend; John C Drach
Journal:  Antimicrob Agents Chemother       Date:  2002-02       Impact factor: 5.191

2.  Effect of six virustatic nucleoside analogues on the development of fetal rat thymus in organ culture.

Authors:  M Foerster; U Kastner; R Neubert
Journal:  Arch Toxicol       Date:  1992       Impact factor: 5.153

3.  Nobel lecture in physiology or medicine--1988. The purine path to chemotherapy.

Authors:  G B Elion
Journal:  In Vitro Cell Dev Biol       Date:  1989-04

4.  Sensitivity of arabinosyladenine-resistant mutants of herpes simplex virus to other antiviral drugs and mapping of drug hypersensitivity mutations to the DNA polymerase locus.

Authors:  D M Coen; H E Fleming; L K Leslie; M J Retondo
Journal:  J Virol       Date:  1985-02       Impact factor: 5.103

5.  Metabolic activation of the nucleoside analog 9-[( 2-hydroxy-1-(hydroxymethyl)ethoxy]methyl)guanine in human diploid fibroblasts infected with human cytomegalovirus.

Authors:  K K Biron; S C Stanat; J B Sorrell; J A Fyfe; P M Keller; C U Lambe; D J Nelson
Journal:  Proc Natl Acad Sci U S A       Date:  1985-04       Impact factor: 11.205

6.  3'-Azido-3'-deoxythymidine inhibits the replication of avian leukosis virus.

Authors:  J C Olsen; P Furman; J A Fyfe; R Swanstrom
Journal:  J Virol       Date:  1987-09       Impact factor: 5.103

7.  Metabolic fate of (E)-5-(2-bromovinyl)-2'-deoxyuridine in herpes simplex virus- and mock-infected cells.

Authors:  N K Ayisi; E De Clercq; R A Wall; H Hughes; S L Sacks
Journal:  Antimicrob Agents Chemother       Date:  1984-11       Impact factor: 5.191

8.  The Epstein-Barr virus thymidine kinase does not phosphorylate ganciclovir or acyclovir and demonstrates a narrow substrate specificity compared to the herpes simplex virus type 1 thymidine kinase.

Authors:  E A Gustafson; A C Chillemi; D R Sage; J D Fingeroth
Journal:  Antimicrob Agents Chemother       Date:  1998-11       Impact factor: 5.191

Review 9.  Glycoprotein targeted therapeutics: a new era of anti-herpes simplex virus-1 therapeutics.

Authors:  Thessicar E Antoine; Paul J Park; Deepak Shukla
Journal:  Rev Med Virol       Date:  2013-02-26       Impact factor: 6.989

10.  Mode of action of (1'S,2'R)-9-[[1',2'-bis(hydroxymethyl) cycloprop-1'-yl]methyl]guanine (A-5021) against herpes simplex virus type 1 and type 2 and varicella-zoster virus.

Authors:  N Ono; S Iwayama; K Suzuki; T Sekiyama; H Nakazawa; T Tsuji; M Okunishi; T Daikoku; Y Nishiyama
Journal:  Antimicrob Agents Chemother       Date:  1998-08       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.